45884XAE3
Intermune Inc
Could not find a ticker for this position, may be a filing error
A California biotechnology company that developed medicines for serious lung and fibrotic diseases. Its best-known product is Esbriet (pirfenidone), a treatment for idiopathic pulmonary fibrosis, a disease that scars lung tissue; it also marketed Actimmune, an interferon-based therapy. Founded in 1998, the company's name is thought to blend "interferon" and "immune," reflecting its early focus. In 2014, Roche bought InterMune, and the company's story later continued under new owners.
CONVERTIBLEUnderlying: ITMNCUSIP: 45884XAE3HealthcareUS1 derivative reporter
2.5% Convertible Senior Notes due 2018
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
